Bergeron, Catherine
Brulotte, Véronique
Pelen, Felix
Clairoux, Ariane
Bélanger, Marie-Eve
Issa, Rami
Urbanowicz, Robert
Tanoubi, Issam
Drolet, Pierre
Fortier, Louis-Philippe
Verdonck, Olivier
Fortier, Annik
Espitalier, Fabien
Richebé, Philippe http://orcid.org/0000-0003-2808-9660
Article History
Received: 13 August 2020
Accepted: 1 December 2020
First Online: 4 January 2021
Compliance with ethical standards
:
: CB, VB, FP, AC, MEB, RI, RU, IT, PD, LPF, OV, AF, FE declare no conflict of interest. P.R. received honorarium as a consultant from the following companies: Medasense, Abbvie, Medtronic-Covidien, Biosyent, Merck. He has been a member of the Scientific Advisory Board of Medasense Ltd. since 2014.
: The trial was conducted at the Maisonneuve-Rosemont University Hospital, University of Montreal, Montreal, QC, Canada. The recruitment was carried out from August 27, 2019 to March 4, 2020. Our research protocol was approved by our institution’s Research Ethics Committee (Comité d’Éthique de la Recherche, installation Hôpital Maisonneuve-Rosemont, CIUSS de l’Est de l’île de Montréal, Montréal, Qc, Canada; CER 2020-1946, August 12th 2019, see annexes). It was registered on clinicaltrial.gov (NCT04060095).
: All patients gave written informed consent.